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Abstract 0 The present study characterized Chinese hamster ovary
cells overexpressing a human intestinal peptide transporter, CHO/
hPEPT1 cells, as an in vitro model for peptidomimetic drugs. The
kinetic parameters of Gly-Sar uptake were determined in three different
cell culture systems such as untransfected CHO cells (CHO−K1),
transfected CHO cells (CHO/hPEPT1) and Caco-2 cells. Vmax in CHO/
hPEPT1 cells was approximately 3-fold higher than those in Caco-2
cells and CHO−K1 cells, while Km values were similar in all cases.
The uptake of â-lactam antibiotics in CHO/hPEPT1 cells was three
to twelve fold higher than that in CHO−K1 cells, indicating that CHO/
hPEPT1 cells significantly enhanced the peptide transport activity.
However, amino acid drugs also exhibited high cellular uptake in both
CHO−K1 and CHO/hPEPT1 cells due to the high background level
of amino acid transporters. Thus, cellular uptake study in CHO/hPEPT1
cells is not sensitive enough to distinguish the peptidyl drugs from
amino acid drugs. The potential of CHO/hPEPT1 cells as an in vitro
model for peptidomimetic drugs was also examined through the
inhibition study on Gly-Sar uptake. Peptidomimetic drugs such as
â-lactam antibiotics and enalapril significantly inhibited Gly-Sar uptake
whereas the nonpeptidyl compounds, L-dopa and R-methyldopa, did
not compete with Gly-Sar for cellular uptake within the therapeutic
concentrations. In conclusion, the present study demonstrates the
further characterization of CHO/hPEPT1 cells as an uptake model as
well as inhibition study and suggests their utility as an alternative in
vitro model for drug candidates targeting the hPEPT1 transporter.
Introduction
Since peptide transporters are potential targets for
improving oral drug absorption through chemical modifica-
tion due to the broad substrate specificity,1,2 an efficient
screening tool is necessary for rapid evaluation of peptidyl
drug candidates arising from rational drug design.
The advantages of in vitro cell cultures over conventional
techniques have been summarized by Audus et al.,3 which
include (a) rapid evaluation of the permeability and
metabolism of a drug, (b) the opportunity to characterize
the molecular mechanism(s) of drug absorption /or drug
metabolism, (c) rapid evaluation of strategies for enhancing
drug absorption and minimizing drug metabolism, (d) the
opportunity to use human cells, rather than animal tissues,
and (e) the opportunity to minimize time-consuming,
expensive, and sometimes controversial animal studies.
Therefore, mammalian cell cultures are increasingly at-
tractive to pharmaceutical scientists as a suitable in vitro
model for drug transport and metabolism studies.
Caco-2 cells are well-characterized4 and currently the
most widely used in vitro cell culture system for intestinal
drug transport studies. However, this cell line exhibits
various transport systems other than peptide transport-
ers,5,6 and it may be difficult to distinguish the responsible
transport system for the test compound. In addition, the
expression level of peptide transporters in Caco-2 cells is
low, variable, and rather insufficient for the screening of
peptidyl drug candidates.7 The advances in the cloning of
peptide transporters and recombinant DNA technology
have recently triggered several attempts to develop a cell
culture model having enhanced peptide transport
activity.8-14 For instance, a human intestinal peptide
transporter, hPEPT1, has been functionally expressed in
HeLa cells13 and also stably transfected into the CHO
cells.14 These overexpression systems provide the analytical
advantage in verifying possible drug candidates with
transport activity mediated via hPEPT1 transporter. Since
the stable transfected cell line, CHO/hPEPT1 has been
characterized only through inhibition studies using some
peptidyl compounds,14 further characterization is necessary
for its wide application as a screening tool of peptidomi-
metic drugs.
In the present study, the functional expression level of
hPEPT1 transporter in CHO/hPEPT1 cells was evaluated
by the kinetic study of Gly-Sar uptake and compared with
those in untransfected CHO cells (CHO-K1) and Caco-2
cells. The potential of CHO/hPEPT1 cells as a screening
tool was examined through the uptake and the inhibition
studies using both peptidyl and nonpeptidyl compounds as
substrates of the hPEPT1 transporter.
Experimental Section
MaterialssGlycyl-[3H]-sarcosine (specific radioactivity, 400
mCi/mmol) was purchased from Moravek Biochemicals Inc. (Brea,
CA). Cephalexin, cephradine, cefaclor, ampicillin, enalapril, glycyl-
sarcosine, L-dopa, and R-methyldopa were purchased from Sigma
Chemical Co. (St. Louis, MO). All tissue culture reagents were
obtained from Gibco (Grand Island, NY). Other chemicals were
either analytical or HPLC grade.
Cell CulturessCHO/hPEPT1 cells were cultured in F-12
nutrition mixture (HAM) containing 10% fetal bovine serum (FBS),
penicillin (100 U/ml)/streptomycin (100 mg/mL), and 200 mg/mL
G418. CHO-K1 cells were cultured in the same media without
G418. Caco-2 cells were routinely maintained in Dulbecco’s
modified Eagle’s medium (DMEM) containing 10% FBS, 1%
nonessential amino acids, 1 mM sodium pyruvate, 1% L-glutamine,
and penicillin (100 U/ml)/streptomycin (100 mg/mL). All cells were
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maintained in an atmosphere of 5% CO2 and 90% relative
humidity at 37 °C.
Kinetic Study of Gly-Sar Uptake in the Different Cell
Culture SystemssCHO/hPEPT1 cells were seeded in 12-well
culture plates at a density of 105 cells/cm2. At 2 days postseeding,
the cells were washed twice with pH 6.0 uptake buffer containing
1 mM CaCl2, 1 mM MgCl2, 150 mM NaCl, 3 mM KCl, 1 mM NaH2-
PO4, 5 mM D-glucose, and 5 mM MES. Gly-Sar solution was
prepared at seven different concentrations (0.01 mM to 50 mM,
0.4 µCi/mL). Each drug solution was added to each well and
incubated at 25 °C. At each time point, cells were washed with
ice-cold pH 6.0 uptake buffer three times to stop the cellular
uptake. One milliliter of 1.5% ice-cold Triton X solution was added
to each well and incubated for 30 min at 25 °C. Cells were
harvested and transferred into vials containing 4 mL of the
scintillation cocktail. Samples were analyzed by a scintillation
counter, and the protein amount of each sample was measured
by the method of Lowry et al.15 Kinetic parameters of Gly-Sar
uptake were also determined in CHO-K1 cells and Caco-2 cells
following the same protocol as was performed in CHO/hPEPT1
cells.
Uptake Study in Both Untransfected and Transfected
CHO Cells. Cells were seeded in six-well culture plates (9.6 cm2,
growth area) at a density of 105 cells/cm2. At 2 days postseeding,
the medium was removed and cells were washed twice with pH
6.0 uptake buffer. Independent studies were performed for each
drug solution at 1 mg/mL made in pH 6.0 uptake buffer. At each
time point (10, 20, 30, 45, 60, 90 min), drug solution was removed
and cells were washed three times with ice-cold pH 6.0 uptake
buffer. One milliliter of Milli-Q water was added to each well and
incubated for 30 min at 25 °C. Cells were harvested and sonicated
for 1-2 min. ZnSO4 solution (8%, 200 mL) was added to the cell
lysate, vortexed rigorously, and centrifuged for 5 min at 3000 rpm.
After filtration of the supernatant through a membrane filter (0.45
mm), samples were analyzed by HPLC. The protein amount of
each sample was determined by the method of Lowry et al.15
Inhibition of Gly-Sar Uptake in CHO/hPEPT1 Cells. Cells
were seeded in 12-well culture plates at a density of 105 cells/cm2.
At 2 days postseeding, the cells were washed twice with pH 6.0
uptake buffer. Each inhibitor solution (0.01 mM to 50 mM)
containing 3H-Gly-Sar (20 mM, 0.4 µCi/ml) was added to each well
and incubated for 30 min at 25 °C. After removing the drug
solution, the cells were washed with ice-cold pH 6.0 uptake buffer
three times to stop the cellular uptake. One milliliter of 1.5% ice-
cold Triton X solution was added to each well and incubated for
30 min at 25 °C. Cells were harvested and transferred into vials
containing 4 mL of scintillation cocktail. Samples were analyzed
by a scintillation counter (Beckman instruments Inc., Model LS-
9000), and the protein amount of each sample was measured by
the method of Lowry et al.15
HPLC AssaysThe instrument consists of a pump (Waters,
Model 510, Milford, MA) and automatic sampler (Model 712 WISP,
Waters) and an UV detector (Waters, 990 Photodiode Array
Detector, Milford, MA). Data acquisition and integration was
carried out using the Millennium software. All compounds were
separated on a reversed phase C-18 column (Beckman Ultra-
sphere, 5 µm, 4.6 × 250 mm) under the conditions published by
Walter et al.16
Data AnalysissEstimate of IC50sIn this study, IC50 is defined
as the drug concentration to show the 50% inhibition of Gly-Sar
uptake. As described by De Lean et al.,17 it was determined from
nonlinear regression of dose-response curve by the Sigma Plot
program (Jandel Scientific, San Rafael, CA) using the equation f
) (a - d)/(1 + (x/c)b) + d, where a and d represent the maximum
and minimum uptake, respectively, x is the inhibitor concentra-
tion, and b is the slope factor.
Determination of Km and VmaxsKm and Vmax for the uptake
of each drug was determined by the nonlinear regression of V )
Vmax ‚ C/(Km + C) + KdC, where KdC represents a diffusional
uptake rate.
Statistical differences between two means were evaluated using
a t-test assuming unequal variance.
Results and Discussion
Uptake Kinetics of Gly-Sar in the Different Cell
Culture SystemssDue to the broad substrate specificity
of the peptide transporter, a wide range of structurally
unrelated molecules have exhibited significant binding
affinity and are transported by the peptide transporter.18-21
Therefore, chemical modification targeting a peptide trans-
porter to improve oral drug absorption is increasingly
attractive to the pharmaceutical scientists. Thus, an ef-
ficient and rapid screening tool is needed to support the
drug discovery process targeting the peptide transporters.
The present study quatitatively evaluated the enhance-
ment of peptide transport activity in CHO/hPEPT1 cells
through the kinetic study of Gly-Sar uptake. Kinetic
parameters of Gly-Sar uptake were determined in CHO/
hPEPT1 cells and compared with those in untransfected
CHO cells and Caco-2 cells which is the most prevalent in
vitro cell culture system for intestinal drug absorption
(Figure 1). As summarized in Table 1. Km values for Gly-
Sar uptake are similar in all three systems, which are
comparable to those in other literatures.11,22 Vmax/Km was
380 for CHO/hPEPT1 cells, which is 2-fold higher than that
for CHO-K1 cells and four times higher than that for
Caco-2 cells. Compared with Kd that indicates the contribu-
tion of passive diffusion, Vmax/Km was approximately 210-
fold, 24-fold, and 17-fold higher in CHO/hPEPT1 cells,
CHO-K1 cells and Caco-2 cells, respectively, indicating
that Gly-Sar uptake was predominantly carrier-mediated.
Furthermore, as shown in Eadie-Hofstee plot (Figure 2),
the cellular uptake of Gly-Sar appeared to be mediated by
a single transporter, even though there are more than one
peptide transporters in CHO/hPEPT1 cells (i.e., hPEPT1
and endogenous peptide transporter) and Caco-2 cells (i.e.,
PEPT1 and HPT1). This is probably due to the wide overlap
of the substrate specificity among peptide transporters and
consequently similar affinity of Gly-Sar to each peptide
transporter. Taken all together, the Gly-Sar kinetic study
indicated that CHO/hPEPT1 cells significantly enhanced
the capacity of the peptide transport system while retaining
the substrate specificity and that this system may be useful
as an in vitro model for the rapid screening of peptidyl
drugs.
Figure 1sKinetic study of Gly-Sar uptake in the different cell culture systems
(n ) 3, mean ± SE). (2) CHO/hPEPT1 cells; (9) CHO−K1 cells; (b) Caco-2
cells.
Table 1sKinetic Parameters of Gly-Sar Uptake in Three Different Cell
Lines (n ) 3, mean ± SE)
CHO/hPEPT1 CHO−K1 Caco-2
Km (mM) 0.5 ± 0.1 0.3 ± 0.1 0.7 ± 0.1
Vmax 211.2 ± 16.4 69.5 ± 6.4 62.5 ± 2.9
(nmol/h/mg protein)
Kd 1.8 ± 0.4 7.7 ± 0.2 5.5 ± 0.1
(nmol/h/mg protein/mM)
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Uptake Studies in Both Transfected and Untrans-
fected CHO CellssThe validity of CHO/hPEPT1 cells as
an uptake model was examined using nonpeptidyl drugs
as well as peptidyl compounds. Cellular uptake of â-lactam
antibiotics was evaluated in CHO/hPEPT1 cells and com-
pared with that in CHO-K1 cells. Initial uptake rate of
each drug was determined from the linearity of time versus
uptake curve. Estimated uptake ratio between CHO/
hPEPT1 cells and CHO-K1 cells (uptake rateCHO/hPEPT1/
uptake rateCHO-K1) was 3.3 for cefaclor, 10.3 for cephalexin,
and 12.1 for cephradine (Figure 3). The cellular uptake of
â-lactam antibiotics was significantly (p < 0.01) increased
in CHO/hPEPT1 cells compared with that in CHO-K1
cells. These results demonstrated that CHO/hPEPT1 cells
greatly enhanced peptide transport activity via the trans-
fection of hPEPT1 gene.
The cellular uptake of L-dopa and R-methyldopa which
are known to be substrates of amino acid transporters23,24
was also evaluated in both CHO/hPEPT1 cells and CHO-
K1 cells. As shown in Figure 3, amino acid analogues,
L-dopa and R-methyldopa, showed significant cellular
uptake in both CHO-K1 cells and CHO/hPEPT1 cells
which were even higher than â-lactam antibiotics. These
results implicated that CHO/hPEPT1 cells expressed a high
background level of the amino acid transport system which
is inherited from the native CHO cells. This explanation
is also supported by other report that CHO cells exhibited
some amino acid transport systems such as system A, ASC,
and L.25 For clarification, the expression level of amino acid
transporters in CHO/hPEPT1 cells should be further
evaluated by using antibodies specific for these transport-
ers. Collectively, due to the high expression of amino acid
transporters, uptake study alone in CHO/hPEPT1 cells is
insufficient for screening peptidomimetic drug candidates.
Inhibition of Gly-Sar Uptake in CHO/hPEPT1
CellssThe potential of CHO/hPEPT1 cells as a rapid
screening tool for peptidyl drug candidates was further
examined through inhibition studies using peptidomimetic
drugs (e.g., â-lactam antibiotics, enalapril) as well as
nonpeptidyl drugs such as L-dopa and R-methyldopa (Fig-
ure 4). IC50 was determined as the drug concentration to
demonstrate 50% inhibition of Gly-Sar uptake and sum-
marized in Table 2. While L-dopa and R-methyldopa did
not inhibit Gly-Sar uptake within the therapeutic concen-
trations, â-lactam antibiotics and enalapril exhibited sig-
nificant inhibition of Gly-Sar uptake (low IC50), implying
that Gly-Sar and the peptidyl derivatives share the same
peptide transport system for cellular uptake. Lower IC50
indicates higher binding affinity to the peptide transporter,
and thus enhancement of peptide transporter-mediated
absorption is expected from lower IC50 values. Carrier-
mediated permeability values (PC*) of â-lactam antibiotics
and enalapril from our previous studies26-28 were compared
with inhibition effects on the peptide transporter (Figure
5). As shown in Figure 5, IC50 values of peptidomimetic
drugs were reciprocally correlated to the intestinal perme-
ability in rats (r2 ) 0.91, p < 0.05). These results suggest
that inhibition studies on Gly-Sar uptake in CHO/hPEPT1
cells may rapidly elucidate the ability of a drug to interact
with the hPEPT1 transporter.
Generally speaking, inhibition studies are not always a
good predictor for the actual cellular uptake of drug
candidates, since binding to a transporter does not neces-
Figure 2sThe Eadie-Hofstee plot of Gly-Sar uptake in the different cell culture
systems (n ) 3, mean ± SE). V and C represent the uptake rate (nmol/h/mg
protein) and Gly-Sar concentration (mM), respectively. (2) CHO/hPEPT1 cells;
(9) CHO−K1 cells; (b) Caco-2 cells.
Figure 3sCellular uptake of peptidyl and nonpeptidyl drugs in CHO/hPEPT1
cells (hatched bars) and in CHO−K1 cells (open bars) (n ) 3, mean ± SE).
(*) indicates p < 0.01.
Figure 4sInhibition of Gly-Sar uptake in CHO/hPEPT1 cells (mean ± SE):
two independent studies were done for each inhibitor and every independent
study had n ) 3. Log C represents the inhibitor concentration.
Table 2sInhibition Effect of Peptidomimetic Drugs on Gly-Sar Uptake
in CHO/hPEPT1 Cells
IC50 (mM)a
Gly-Sar 0.7 ± 0.1
enalapril 4.5 ± 0.7
cefaclor 8.2 ± 1.8
cephalexin 13.7 ± 3.0
cephradine 15.3 ± 2.4
ampicillin 47.4 ± 6.0
L-dopa 141.2 ± 40.4
methyldopa 151.6 ± 21.4
a IC50 was determined from two independent studies, and each study has
n ) 3, mean ± SE.
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sarily guarantee drug transport into cells. However, false
positives may do little harm in the discovery of drug
candidates for oral administration, since they can be
excluded by further evaluation. Therefore, competitive
inhibition studies in CHO/hPEPT1 cells as well as Caco-2
cells could be used for the initial screening of promising
candidates from the various drug derivatives, and then
more rigorous studies are necessary for further screening
of drug candidates.
In conclusion, our present study can be summarized as
follows. First, CHO/hPEPT1 cells significantly enhanced
peptide transport activity via overexpression of hPEPT1
gene. Second, due to the high background level of amino
acid transporters, the cellular uptake study alone in CHO/
hPEPT1 cells is insufficient for the screening of peptidyl
drugs. Third, inhibition study in CHO/hPEPT1 cells can
be served as an alternative in vitro model to support the
drug discovery process targeting the peptide transporter.
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